National Vision Holdings, Inc.

National Vision Holdings, Inc. (EYE) Market Cap

National Vision Holdings, Inc. has a market capitalization of $2.04B.

Financials based on reported quarter end 2026-01-03

Price: $25.68

0.81 (3.26%)

Market Cap: 2.04B

NASDAQ · time unavailable

CEO: Alexander N. Wilkes

Sector: Consumer Cyclical

Industry: Specialty Retail

IPO Date: 2017-10-27

Website: https://www.nationalvision.com

National Vision Holdings, Inc. (EYE) - Company Information

Market Cap: 2.04B · Sector: Consumer Cyclical

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. As of January 1, 2022, the company operated through 1,278 retail stores, as well as various e-commerce websites. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

Analyst Sentiment

76%
Strong Buy

Based on 11 ratings

Analyst 1Y Forecast: $31.33

Average target (based on 3 sources)

Consensus Price Target

Low

$30

Median

$35

High

$40

Average

$35

Potential Upside: 37.1%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 NATIONAL VISION HOLDINGS INC (EYE) — Investment Overview

🧩 Business Model Overview

National Vision Holdings Inc (NVI, trading as EYE) is a leading optical retail and eye care company in the United States, specializing in affordable eye care and eyewear solutions. The company operates a diverse portfolio of value-oriented retail brands and offers accessible optical services to a broad, often under-served, customer base. Through both company-owned and partnership locations—such as those with retail giants and in military exchanges—National Vision delivers routine eye exams, prescription eyewear, contact lenses, and related products. The company's business model emphasizes cost efficiency and scalability, leveraging centralized lab facilities and supply chain capabilities to maintain low-price points, while fostering steady traffic through a mix of in-store and digital sales channels.

💰 Revenue Streams & Monetisation Model

National Vision derives revenues from several complementary sources:
  • Retail Optical Sales: Sales of prescription and non-prescription eyeglasses, contact lenses, and accessories across various brand formats, with America's Best and Eyeglass World as the flagship stores.
  • Comprehensive Eye Exams: Fees from routine eye exams, largely performed by independent optometrists operating on or adjacent to store premises, provide recurring, stable service revenue.
  • Third-Party Arrangements: Management and operation of optical departments within large retail partners (notably Walmart, in a legacy agreement), as well as contracts for serving U.S. military exchanges.
  • Online Sales: E-commerce platforms for eyewear and contact lenses, providing incremental reach and sales.
The company's monetization is anchored in high transaction volumes driven by affordable pricing, and by targeting a price-sensitive demographic with limited alternatives for low-cost optical care.

🧠 Competitive Advantages & Market Positioning

National Vision occupies a differentiated position within the U.S. optical retail landscape:
  • Value Leadership: With a strict focus on affordability and bundled pricing, NVI attracts a demographic for whom cost is a primary barrier to eye care.
  • Scale and Operational Efficiency: Centralized manufacturing labs enable quality eyewear production at scale, supporting low retail prices and rapid fulfillment.
  • Strategic Partnerships: National Vision's longstanding relationships with large retailers and military exchanges consolidate its reach and create cost-sharing opportunities that smaller competitors cannot easily replicate.
  • Omnichannel Presence: The integration of digital sales with an extensive brick-and-mortar footprint enables frictionless customer experiences that bridge convenience with accessibility.
  • Resilient End-Market: Vision correction is a non-discretionary health need, which provides underlying revenue stability even during economic downturns.
In a market characterized by both large vertically integrated competitors and fragmented independents, NVI’s niche in providing low-cost care at scale gives it a durable edge.

🚀 Multi-Year Growth Drivers

Several secular and company-specific trends underpin National Vision’s long-term growth thesis:
  • Expanding U.S. Optical Market: Aging demographics and increasing screen usage are fueling greater demand for vision correction and eye health services.
  • Rising Insurance Coverage & Health Awareness: Broadening access to managed vision care and public health initiatives promote more frequent eye exams and eyewear purchases among new demographics.
  • Store Network Expansion: Opportunities remain for disciplined unit growth in under-penetrated geographies, especially in communities with limited eye care access.
  • Digital Channel Scaling: Investments in omnichannel capabilities, tele-optometry, and e-commerce stand to capture additional share as consumer preferences evolve.
  • Partnership and B2B Opportunities: Existing and potential future partnerships with mass retailers and institutional clients (such as government or military) could unlock new captive customer pools.
  • Operational Leverage: As business scales, fixed-cost absorption in central labs and supply chains may support margin expansion over time.

⚠ Risk Factors to Monitor

Potential challenges and headwinds for National Vision include:
  • Consumer Pressure: A value-based customer base is highly sensitive to wage pressure, economic slowdowns, and out-of-pocket healthcare expense trends, which could impact transaction volumes.
  • Third-Party Contract Dependencies: Reliance on key retail partnerships for store locations leaves the company exposed to partnership changes, non-renewal risks, or adverse renegotiations.
  • Labor Market Tightness: Recruiting and retaining optometrists and trained staff can be challenging in a competitive healthcare labor environment.
  • Margin Compression: The constant need to offer competitive pricing, as well as cost inflation in labor, rent, and materials, may pressure margins absent offsetting scale or productivity gains.
  • Regulatory and Reimbursement Risk: Evolving healthcare regulation, potential changes in insurance reimbursement, or stricter optical industry standards may add operational complexity or costs.
  • Digital Disruption: Growth in online-only eyewear competitors and telehealth could erode market share if the company fails to keep pace with innovation.

📊 Valuation & Market View

National Vision is typically valued using a combination of earnings-based multiples (such as EV/EBITDA and P/E) compared to peers in the healthcare retail and optical sectors. Its valuation reflects a blend of stable, defensive healthcare-like characteristics and discretionary retail growth prospects. The company’s market position as a low-cost provider with embedded growth opportunities may command a premium relative to smaller, less-scaled specialty retailers, but trade at a discount to larger, vertically integrated healthcare companies. Key valuation variables include the pace of same-store sales growth, the margin trajectory as scale increases, and the durability of strategic partnerships. Equity analysts generally weigh the company’s defensive model, expansion runway, and resilient cash flow profile against operational and partnership execution risks. The stock’s market standing is also shaped by perceptions about management’s ability to sustain growth without sacrificing the low-price value proposition.

🔍 Investment Takeaway

National Vision Holdings provides a unique investment opportunity within the broader optical and healthcare retail landscape. The company’s disciplined focus on affordable, accessible eye care drives high transaction volumes and a loyal customer base, while enjoying defensive demand characteristics tied to essential health needs. Secular trends in vision care demand, demographic shifts, and digital adoption create a multi-year growth runway, further amplified by potential store network expansion and operational leverage. However, the path forward requires vigilance regarding consumer spending trends, evolving competitor actions (particularly in the digital channel), partnership dependencies, and ongoing margin pressures. Long-term investors should focus on management’s execution in balancing expansion, operational efficiency, and value leadership to sustain National Vision’s growth thesis. For those seeking exposure to healthcare-adjacent retail with secular underpinnings and proven scalability, National Vision Holdings warrants careful consideration within a diversified portfolio.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-01-03

"EYE reported a revenue of $503.4M and a net income of $3.32M for the most recent quarter. Despite a revenue figure indicative of a solid operation, the company is struggling with negative operating cash flow of -$133.1M and a free cash flow of -$84.7M, which raises concerns about its cash flow quality. The total assets stand at $2.13B against total liabilities of $1.26B, giving it a solid equity position of $869.5M, although net debt is a significant $655.9M. The company is experiencing impressive market performance, with a one-year price change of 102.06%, signaling strong investor interest and boosting its score for shareholder returns. However, the stock has not produced dividends. Overall, its valuation metrics remain to be analyzed in further detail, especially what this implies for future profitability and growth prospects."

Revenue Growth

Positive

Revenue of $503.4M indicates growth potential.

Profitability

Fair

Positive net income, but relatively low compared to revenue.

Cash Flow Quality

Neutral

Negative operating cash flow; concerns regarding cash sustainability.

Leverage & Balance Sheet

Neutral

Healthy equity position but significant net debt.

Shareholder Returns

Good

Strong price appreciation of over 100% in the past year.

Analyst Sentiment & Valuation

Neutral

Market performance is solid; valuation metrics need further insight.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management delivered strong FY2025 and Q4 execution: FY2025 net revenue +9%, adjusted comp +6%, and AOI margin +160 bps to 5.2%, with adjusted EPS $0.80 (+~54%). Q4 showed clear operating leverage—adjusted operating margin up +280 bps to 3.5%—and adjusted EPS swung to $0.15 from a loss. However, the quarter’s traffic/comps were distorted by a hard calendar factor: losing one high-volume selling day tied to the 53rd-week impact (estimated ~50 bps drag on Q4 traffic comp). The only analyst pressure visible in the transcript is a direct concern about whether growth from richer-pay (insurance/managed care/progressive/Outside Rx) could eventually pause as the company’s mix shifts away from traditional customers. The excerpt cuts off before any concrete answer on that risk. Net: results are strong, but the Q&A thrust suggests investors are focused on durability of the trade-off, not just margin progress.

AI IconGrowth Catalysts

  • Managed care/progressive/Outside Rx traffic growth in Q4 (combined) alongside strong average ticket growth
  • Meta AI glasses sell-through exceeding expectations; availability expanded to 300 stores by Q4 with plan to be in all stores by end of Q2
  • Shift to more profitable customer mix (managed care + progressive + Outside Rx) supported by new store selling techniques and merchandising approach
  • Premium frame and branded assortment expansion (branded frames added; shift in mix of frames priced above $99)

Business Development

  • Meta AI glasses rollout via store availability expansion (300 stores by Q4; all stores by end of Q2)
  • Branded frame introductions including Lam, Ted Baker, Hugo Boss, Jimmy Choo, Kendra Scott (plus planned additional brands listed for 2026: Burberry, True Religion, Kate Spade, Polo Ralph Lauren, Costa)
  • New marketing/media partner planned for 2026: Infinite Roar
  • Mentioned marketing/creative work for America’s Best by VML (Eyeglass World update expected later in the year)

AI IconFinancial Highlights

  • FY2025 net revenue +9% to $1.99B
  • FY2025 adjusted comp store sales +6%
  • FY2025 adjusted operating income +56% to $102.5M; AOI margin expansion +160 bps to 5.2%
  • FY2025 adjusted EPS $0.80 vs $0.52 in 2024 (up ~54%)
  • Q4 net revenue +15.1% to $503M
  • Q4 adjusted comp store sales +4.8%
  • Q4 adjusted operating income $17.6M; adjusted operating margin +280 bps to 3.5% (vs 0.7% in prior-year Q4)
  • Q4 adjusted EPS $0.15 vs loss of $0.04 prior year
  • Costs applicable to revenue decreased ~40 bps (Q4)
  • Adjusted SG&A leveraged +180 bps as % of revenue in Q4
  • Q4 operational headwind: 53rd-week/calendar shift created negative impact; lost one high-volume selling day in comp calendar that would have added ~+50 bps improvement in Q4 traffic comp
  • Q4 doctor incentive true-up lapped: slight increase in optometrist-related costs due to lapping a prior-year one-time benefit
  • Interest rate hedge entered in Q4 on $100M debt: fixed rate 3.43% to reduce short-term rate volatility
  • FY2026 outlook: net revenue $2.03B-$2.09B; adjusted comp store sales +3%-6%
  • FY2026 outlook: adjusted operating income $107M-$133M; midpoint implies ~+100 bps adjusted operating margin expansion vs FY2025 (excluding 53rd week), driven primarily by SG&A leverage
  • FY2026 adjusted diluted EPS guidance: $0.85-$1.09 (assumes ~82M weighted average diluted shares)
  • FY2026 effective tax rate ~28% excluding vesting/option exercise impacts

AI IconCapital Funding

  • Cash balance end of FY2025: $38.7M; total liquidity $332M (incl. revolver capacity)
  • Debt: repaid $101.3M long-term debt convertible notes; total debt outstanding (net of discounts) $245.9M at end of 2025; net debt / adjusted EBITDA 1.1x
  • Share repurchase authorization: Board approved repurchase up to $50M until Dec 28, 2030
  • FY2025 capex: $72.8M
  • FY2026 capex expected: $73M-$78M
  • FY2026 store growth plan: open ~30-35 new stores; close ~10-15 stores (net +20-25)

AI IconStrategy & Ops

  • Merchandising/premiumization: frames priced above $99 increased to ~40% of frames from 20% at start of year
  • Consultative selling model: deployed iPads/digital tools and updated in-store environment (graphics, pricing presentation, signage, associate dress standards) with 'modest investments' and 'without significant capital intensity'
  • Remote/hybrid exam model: expanded number of doctors trained and participating; remote exam tech continues to provide network capacity flexibility
  • Eyeglass World operating changes: step to employed OD model to standardize execution/patient experience; brand positioning refinement underway
  • Customer experience tech: first phases of Adobe Digital Experience Platform in 2025; plan to expand across brands in 2026 and deepen integration with in-store experience
  • ERP/data platforms: new end-to-end Oracle ERP launched in 2025; ongoing investments in Microsoft/Databricks data warehouses and analytics platforms
  • Lapsed customer journey: early results in Q4 nearly 2x effectiveness vs old approach (on smaller base)

AI IconMarket Outlook

  • FY2026 net revenue guidance: $2.03B-$2.09B
  • FY2026 adjusted comp store sales: +3%-6%
  • FY2026 adjusted operating income: $107M-$133M; midpoint implies ~+100 bps margin expansion vs FY2025 (excluding 53rd week)
  • FY2026 adjusted diluted EPS: $0.85-$1.09
  • FY2026 quarterly margin pattern: Q1 and Q3 more favorable YoY growth; Q2 and Q4 flat to modest growth (reflects returning to 52-week year + loss of 53rd week, holiday shifts, and investment timing)

AI IconRisks & Headwinds

  • Q4 comps/traffic headwind from calendar: 53rd-week impact caused loss of one high-volume selling day; management estimated this would have been ~+50 bps improvement in Q4 traffic comp absent the calendar shift
  • Near-term traffic mix risk implied by Q&A theme (not answered in provided transcript excerpt): possibility of a 'pause' in growth/trade-off between richer-pay insurance/progressive/managed care cohorts vs traditional customer base
  • Planned customer mix shift expected to reduce overall traffic in the short term: traffic declined ~0.5% overall in FY2025 due to self-pay declines offset by gains in profitable cohorts
  • Weather challenges: management referenced weather impacting 1QTD and still expects mid-single-digit comp store sales

Sentiment: MIXED

Note: This summary was synthesized by AI from the EYE Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (EYE)

© 2026 Stock Market Info — National Vision Holdings, Inc. (EYE) Financial Profile